Neladenoson bialanate

Drug Profile

Neladenoson bialanate

Alternative Names: BAY 1067197

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Heart failure therapies
  • Mechanism of Action Adenosine A1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic heart failure

Most Recent Events

  • 07 Apr 2017 Bayer plans the PANACHE phase II trial for Chronic heart failure in USA, Austria, Belgium, Bulgaria, Germany, Greece, Israel, Italy, Poland, Portugal and Spain (NCT03098979)
  • 09 Mar 2017 Bayer initiates the phase II PANTHEON trial for Chronic heart failure (patients with reduced ejection fraction) in Germany (PO) (EudraCT2016-003839-38)
  • 06 Mar 2017 Phase-II development for Chronic heart failure is ongoing in Germany, Italy, Netherlands and Poland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top